Hyperlipidemia is common in type 2 diabetic patients and is an independent risk factor for
cardiovascular disease. The aim of this trial was to evaluate the efficacy and safety of once-daily
atorvastatin 10-80 mg for the treatment of
hyperlipidemia in type 2 diabetics with plasma
low-density lipoprotein cholesterol (
LDL-C) levels exceeding 3.4 mmol/l (130 mg/dl). One hundred and two patients met the study criteria and received 10 mg/day
atorvastatin. Patients who reached the target
LDL-C level of </=2.6 mmol/l (100 mg/dl) maintained the same dosage regimen until they had completed 16 weeks of treatment. Patients not reaching the target
LDL-C underwent dose titration to
atorvastatin 20, 40 and 80 mg/day at Weeks 4, 8 and 12, respectively. All 88 patients who completed the study attained target
LDL-C levels and 52 (59%) of patients achieved the target goal at the starting dose of
atorvastatin 10 mg/day. In this group the differences between baseline and post-treatment values for
LDL-C were 4.3+/-0.7 mmol/l (166+/-26 mg/dl) versus 2. 2+/-0.4 mmol/l (87+/-14 mg/dl) (P<0.0001), respectively, a decrease of 47%. Similar trends were observed for total
cholesterol,
triglycerides,
very low-density lipoprotein cholesterol and
apolipoprotein B levels. The safety profile of
atorvastatin in these patients was highly favorable and similar to those reported with other
statins. Only one patient withdrew due to a possible
drug-related adverse event. These data confirm the marked efficacy and safety of
atorvastatin in type 2 diabetic patients with
hyperlipidemia and the efficacy of
atorvastatin 10 mg in helping patients attain their
LDL-C goal.